About tenaya therapeutics inc - TNYA
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.
TNYA At a Glance
Tenaya Therapeutics, Inc.
171 Oyster Point Boulevard
South San Francisco, California 94080
| Phone | 1-650-825-6990 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -90,597,000.00 | |
| Sector | Health Technology | Employees | 70 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TNYA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.251 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.225 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.566 |
TNYA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,294,242.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TNYA Liquidity
| Current Ratio | 6.84 |
| Quick Ratio | 6.84 |
| Cash Ratio | 6.514 |
TNYA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -66.456 |
| Return on Equity | -83.84 |
| Return on Total Capital | -67.562 |
| Return on Invested Capital | -77.183 |
TNYA Capital Structure
| Total Debt to Total Equity | 8.786 |
| Total Debt to Total Capital | 8.076 |
| Total Debt to Total Assets | 7.253 |
| Long-Term Debt to Equity | 6.336 |
| Long-Term Debt to Total Capital | 5.824 |